Alzheimer's Disease

AC Immune SA ad Takeda have announced an exclusive, worldwide option and license agreement for the former’s active immunotherapies that target toxic forms of the biomarker amyloid beta to treat Alzheimer’s disease.

The FDA’s approval of Leqembi in July 2023 triggered a wave of discussion in the medical community on how to prescribe and properly administer the amyloid-targeting antibody to treat those diagnosed with Alzheimer’s disease.

DENVER — Treatment with a novel, oral receptor agonist led to rapid and significant improvements in those with agitation related to Alzheimer’s disease, according to a speaker at the American Academy of Neurology annual meeting.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

The FDA has granted breakthrough device designation to a blood-based biomarker test to more quickly detect amyloid presence in individuals with suspected Alzheimer’s disease, according to the manufacturer.

Higher education levels may protect against cognitive and functional difficulties for Black individuals with high levels of tau, indicating Alzheimer’s pathology, according to research from the Journal of Alzheimer’s Disease.

Eisai and Biogen have submitted a supplemental biologics license application to the FDA for monthly IV maintenance dosing of Leqembi to treat Alzheimer’s disease in patients with mild cognitive impairment or mild dementia.

IGC Pharma has announced positive interim results from an ongoing phase 2 trial investigating IGC-AD1, a natural THC-based oral formulation, as a treatment for agitation in dementia from Alzheimer’s disease.

Bristol Myers Squibb has completed its acquisition of Karuna Therapeutics, including Karuna’s therapeutic portfolio featuring a novel, investigational muscarinic antipsychotic to treat schizophrenia and Alzheimer’s disease.